12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lorvotuzumab mertansine: Additional Phase I data

Data from 39 evaluable patients in an expansion cohort of the open-label, dose-escalation, U.S. Phase I Study 005 trial showed that once-weekly 75 mg/m 2 IMGN901 for 3 weeks of a 4-week cycle plus lenalidomide and dexamethasone led to a clinical response rate, defined as a minimal response or better, of 64%. Additionally, 31% of patients had stable disease and 31% had...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >